Trial Site Detail
Drug: |
MRTX1719 |
|||
|---|---|---|---|---|
Trial: |
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion |
|||
| Conditions: | Solid Tumors | |||
Trial Status: |
Recruiting |
|||
Sarah Cannon Research Institute3322 West End Avenue Suite 900 |
Principal Investigator: |
|
|---|---|
Contact: |
Melissa Johnson 615-329-7274 |
Activation Status of this Site: |
Active |
Notes about this Site: |
|
Sarah Cannon Research Institute Website: |
http://www.sarahcannonresearch.com/CustomPage.asp?PageName=Refractory%20Malignancies |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.